Arcutis Biotherapeutics, Inc. ARQT Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five?
- Arcutis Biotherapeutics, Inc. (ARQT) reported debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five of $49.03M in Q1 2026.